Literature DB >> 26892520

Associations of insulin resistance, inflammation and liver synthetic function with very low-density lipoprotein: The Cardiovascular Health Study.

Z Gordon Jiang1, Ian H de Boer2, Rachel H Mackey3, Majken K Jensen4, Michelle Lai5, Simon C Robson5, Russell Tracy6, Lewis H Kuller7, Kenneth J Mukamal8.   

Abstract

INTRODUCTION: Production of very low-density lipoprotein (VLDL) is increased in states of metabolic syndrome, leading to hypertriglyceridemia. However, metabolic syndrome is often associated with non-alcoholic fatty liver disease, which leads to liver fibrosis and inflammation that may decrease VLDL production. In this study, we aim to determine the interactive impact on VLDL profiles from insulin resistance, impairment in liver synthetic function and inflammation.
METHODS: We examined cross-sectional associations of insulin sensitivity, inflammation, and liver synthetic function with VLDL particle (VLDL-P) concentration and size among 1,850 older adults in the Cardiovascular Health Study.
RESULTS: Indices for high insulin sensitivity and low liver synthetic function were associated with lower concentrations of VLDL-P. In addition, insulin resistance preferentially increased concentration of large VLDL and was associated with mean VLDL size. Indices for inflammation however demonstrated a nonlinear relationship with both VLDL-P concentration and VLDL size. When mutually adjusted, one standard deviation (SD) increment in Matsuda index and C-reactive protein (CRP) were associated with 4.9 nmol/L (-8.2 to -1.5, p=0.005) and 6.3 nmol/L (-11.0 to -1.6, p=0.009) lower VLDL-P concentration respectively. In contrast, one-SD increment in factor VII, a marker for liver synthetic function, was associated with 16.9 nmol/L (12.6-21.2, p<0.001) higher VLDL-P concentration. Furthermore, a one-SD increment in the Matsuda index was associated with 1.1 nm (-2.0 to -0.3, p=0.006) smaller mean VLDL size, whereas CRP and factor VII were not associated with VLDL size.
CONCLUSION: Insulin sensitivity, inflammation and markers for liver synthetic function differentially impact VLDL-P concentration and VLDL size. These results underscore the complex effects of insulin resistance and its complications on VLDL production.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Insulin resistance; Liver synthetic function; Non-alcoholic fatty liver disease (NAFLD); Non-alcoholic steatohepatitis (NASH); Very low-density lipoprotein (VLDL)

Mesh:

Substances:

Year:  2015        PMID: 26892520      PMCID: PMC4761104          DOI: 10.1016/j.metabol.2015.10.017

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  35 in total

Review 1.  Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy.

Authors:  James D Otvos
Journal:  Clin Lab       Date:  2002       Impact factor: 1.138

Review 2.  Nonalcoholic fatty liver disease.

Authors:  Paul Angulo
Journal:  N Engl J Med       Date:  2002-04-18       Impact factor: 91.245

Review 3.  Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition.

Authors:  Scott M Grundy; H Bryan Brewer; James I Cleeman; Sidney C Smith; Claude Lenfant
Journal:  Circulation       Date:  2004-01-27       Impact factor: 29.690

4.  Multiple imputation of baseline data in the cardiovascular health study.

Authors:  Alice M Arnold; Richard A Kronmal
Journal:  Am J Epidemiol       Date:  2003-01-01       Impact factor: 4.897

5.  Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement.

Authors:  J D Otvos; E J Jeyarajah; D W Bennett; R M Krauss
Journal:  Clin Chem       Date:  1992-09       Impact factor: 8.327

6.  The Cardiovascular Health Study: design and rationale.

Authors:  L P Fried; N O Borhani; P Enright; C D Furberg; J M Gardin; R A Kronmal; L H Kuller; T A Manolio; M B Mittelmark; A Newman
Journal:  Ann Epidemiol       Date:  1991-02       Impact factor: 3.797

7.  Apolipoprotein synthesis in nonalcoholic steatohepatitis.

Authors:  Michael Charlton; Raghavakaimal Sreekumar; Deborah Rasmussen; Keith Lindor; K Sreekumaran Nair
Journal:  Hepatology       Date:  2002-04       Impact factor: 17.425

8.  Laboratory methods and quality assurance in the Cardiovascular Health Study.

Authors:  M Cushman; E S Cornell; P R Howard; E G Bovill; R P Tracy
Journal:  Clin Chem       Date:  1995-02       Impact factor: 8.327

9.  Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.

Authors:  D R Matthews; J P Hosker; A S Rudenski; B A Naylor; D F Treacher; R C Turner
Journal:  Diabetologia       Date:  1985-07       Impact factor: 10.122

10.  Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study.

Authors:  Lewis Kuller; Alice Arnold; Russell Tracy; James Otvos; Greg Burke; Bruce Psaty; David Siscovick; David S Freedman; Richard Kronmal
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-07-01       Impact factor: 8.311

View more
  8 in total

1.  Research advances in metabolism 2016.

Authors:  Nikolaos Perakakis; Olivia M Farr; Dario Tuccinardi; Jagriti Upadhyay; Christos S Mantzoros
Journal:  Metabolism       Date:  2016-11-06       Impact factor: 8.694

Review 2.  Nonalcoholic fatty liver disease: implications for cardiovascular risk.

Authors:  Amreen Dinani; Arun Sanyal
Journal:  Cardiovasc Endocrinol       Date:  2017-05-17

3.  Moderate alcohol consumption and lipoprotein subfractions: a systematic review of intervention and observational studies.

Authors:  Trine L Wilkens; Kaare Tranæs; Jane N Eriksen; Lars O Dragsted
Journal:  Nutr Rev       Date:  2022-04-08       Impact factor: 6.846

4.  Hemoglobin level and lipoprotein particle size.

Authors:  Päivi Hämäläinen; Juha Saltevo; Hannu Kautiainen; Pekka Mäntyselkä; Mauno Vanhala
Journal:  Lipids Health Dis       Date:  2018-01-10       Impact factor: 3.876

5.  Impaired HDL2-mediated cholesterol efflux is associated with metabolic syndrome in families with early onset coronary heart disease and low HDL-cholesterol level.

Authors:  Timo Paavola; Sanna Kuusisto; Matti Jauhiainen; Sakari Kakko; Tiia Kangas-Kontio; Jari Metso; Pasi Soininen; Mika Ala-Korpela; Risto Bloigu; Minna L Hannuksela; Markku J Savolainen; Tuire Salonurmi
Journal:  PLoS One       Date:  2017-02-16       Impact factor: 3.240

6.  Dietary Fiber Is Independently Related to Blood Triglycerides Among Adults with Overweight and Obesity.

Authors:  Bridget A Hannon; Sharon V Thompson; Caitlyn G Edwards; Sarah K Skinner; Grace M Niemiro; Nicholas A Burd; Hannah D Holscher; Margarita Teran-Garcia; Naiman A Khan
Journal:  Curr Dev Nutr       Date:  2018-11-28

7.  Fatty liver index as a predictor of increased risk of cardiometabolic disease: finding from the Kuopio Ischaemic Heart Disease Risk Factor Study Cohort.

Authors:  Olubunmi O Olubamwo; Jyrki K Virtanen; Jussi Pihlajamaki; Pekka Mantyselka; Tomi-Pekka Tuomainen
Journal:  BMJ Open       Date:  2019-09-05       Impact factor: 2.692

Review 8.  Metabolic-associated fatty liver disease and lipoprotein metabolism.

Authors:  Joerg Heeren; Ludger Scheja
Journal:  Mol Metab       Date:  2021-04-20       Impact factor: 7.422

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.